{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:14:06Z","timestamp":1726503246215},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3509","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.46883\/onc.2021.3509.0562","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T14:47:56Z","timestamp":1631803676000},"page":"562-566","source":"Crossref","is-referenced-by-count":1,"title":["Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2021,9,16]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T14:47:57Z","timestamp":1631803677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/oligoprogression-after-immunotherapy-and-targeted-therapy-in-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":0,"issue-title":["September 2021"],"journal-issue":{"issue":"3509","published-online":{"date-parts":[[2021,9,14]]},"published-print":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.46883\/onc.2021.3509.0562","relation":{},"ISSN":["0890-9091"],"issn-type":[{"type":"print","value":"0890-9091"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}